1. Introduction {#sec1}
===============

Autoimmune hepatitis (AIH) is a rare chronic form of hepatitis characterized by specific liver histopathology, blood biochemistry, and serology with a prevalence of 11--25 per 100,000 population \[[@bib1]\]. Autoimmune hepatitis is more common among females and often appears at between 40 and 50 years of age \[[@bib2], [@bib3]\]. AIH has two types: type 1 AIH which is defined by the presence of circulating antinuclear antibodies (ANA) and/or anti-smooth muscle antibodies (ASMA); and type 2 which is characterized by the presence of antibodies to liver/kidney microsomes (ALKM-1) and/or to a liver cytosol antigen (ALC-1) \[[@bib2], [@bib4]\]. Liver cirrhosis and liver failure usually occur in patients with untreated or unresponsive to treatment, and such patients are at risk of developing hepatocellular carcinoma \[[@bib5]\].

Standard first-line immunosuppressive treatment of autoimmune hepatitis comprises one of two regimens, which are equally effective against severe AIH: (a) high-dose prednisolone monotherapy or half-dose prednisolone therapy in conjunction with azathioprine \[[@bib6], [@bib7]\]. Prednisolone monotherapy is appropriate for patients with cytopenia, thiopurine methyltransferase deficiency, pregnancy, or malignancy \[[@bib8]\]. The combination therapy results in fewer corticosteroid side-effects and is preferred for patients with brittle diabetes, osteoporosis, obesity, or hypertension, or who are post-menopausal or emotionally unstable. Untreated AIH has a poor prognosis with a 5-year survival rate of 50% and 10-year survival rate of 10% \[[@bib9]\]. Immunosuppressive therapy significantly improves survival, with 90% of treated AIH patients achieving complete remission \[[@bib7], [@bib10], [@bib11], [@bib12]\]. Some small studies have shown that cirrhosis at the time of diagnosis---with a high MELD score, high AST/ALT, high serum IgG, or overlapping syndromes---is associated with poor treatment outcomes \[[@bib11], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]\]. Notwithstanding, the median time to remission, prognostic factors of remission, relapse rate, and complication rate of the two treatment regimens in AIH patients have not been compared.

The current study thus aimed to define the prognostic factors for remission and compared the median time to remission, complications, and relapse rate between type 1 AIH patients treated with prednisolone monotherapy and those given a combination regimen.

2. Materials and methods {#sec2}
========================

This was a retrospective study conducted at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University. Our protocol was approved by the Khon Kaen University Ethics Committee for Human Research (Reference No.HE601224). We reviewed the records of patients with AIH registered in the hospital\'s electronic medical records between January 1998 and January 2018. The inclusion criteria were diagnosis with AIH based on the International Autoimmune Hepatitis Group\'s simplified diagnostic criteria \[[@bib18]\], any the Child Pugh score including overlapping diseases \[[@bib19], [@bib20], [@bib21]\] from the in- or out-patient department, and being at least 18 years of age. Patients were excluded if they were pregnant, had a history of liver transplantation, and diagnosed with other conditions such as non-alcoholic steatohepatitis, lupus hepatitis, and herb-induced hepatitis.

Patient clinical data and laboratory results were collected from both electronic and paper medical records. At their initial visit, all eligible patients were assessed based on serum biochemistry, serum immunoglobulins, serum autoantibodies, viral markers, and liver histology. According to the simplified diagnostic criteria \[[@bib18]\], patients with greater than 6 points, 6 points, and less than 6 points, were classified as having definite, probable, and possible AIH, respectively. At subsequent follow-up visits, each patient treatment regimen, additional medications, follow-up laboratory results, and treatment complications were recorded until the treatment endpoint had been reached. The treatment endpoint was classified as a) complete remission -- defined as the disappearance of symptoms and normal serum aminotransferase and bilirubin levels; b) incomplete remission -- defined as some or no improvement in clinical and laboratory results despite compliance with therapy after 2--3 years; and, c) treatment failure -- defined as worsening of clinical and laboratory results despite compliance with therapy \[[@bib2]\].

The primary outcome was prognostic factors for remission of AIH. The secondary outcomes were differences in median time to AIH remission, complication rates, and relapse rates between patients given prednisolone monotherapy and those treated with prednisolone in combination with azathioprine. The baseline characteristics of each treatment endpoint were compared using descriptive statistics. Differences in median time to remission between the two groups were analyzed and summarized using Kaplan-Meier curves. The Cox-proportional hazard model was applied to calculate the crude hazard ratios of variables associated with complete remission. Multivariable analysis was performed to calculate the adjusted hazard ratios. Pearson\'s chi-squared test was applied to compare the treatment complications between the two regimens. Logistic regression analysis was used to calculate the odds ratio of the relapse rates of the two regimens. All analyses were performed using STATA and RStudio software.

3. Results {#sec3}
==========

During the 20-year study period, a total of 239 patients were registered as having autoimmune hepatitis at Srinagarind Hospital, 86 of whom were diagnosed with type 1 AIH and enrolled in the current study ([Figure 1](#fig1){ref-type="fig"}). The others were diagnosed with other conditions such as non-alcoholic steatohepatitis, lupus hepatitis, and herb-induced hepatitis. Initial treatment included prednisolone monotherapy (n = 42) and prednisolone in combination with azathioprine (n = 44). Sixty-two of the 86 enrolled patients (72.1%) experienced complete remission, while 13 (15.1%) and 11 (12.8%) had incomplete remission and were lost to follow-up, respectively. No patients experienced treatment failure. The average duration of follow-up was 2 years (SD 3 years). Baseline characteristics and laboratory results by treatment endpoint are shown in [Table 1](#tbl1){ref-type="table"}. Eighty percent of patients were female. There were no significant differences in age, BMI, or azathioprine exposure among the three groups. The majority (67.4%) of patients was considered to have possible autoimmune hepatitis based on the autoimmune hepatitis diagnostic criteria. The number of patients with no underlying diseases was significantly lower in the incomplete remission group than in the other two groups, while the number of patients with hypertension was significantly greater. Serum albumin was significantly lower and serum total bilirubin and alkaline phosphatase were significantly higher in the lost to follow-up group than the other groups. Diagnostic classifications, ultra-sonographic findings, liver histopathology, and the Child-Pugh scores differed significantly among the three groups ([Table 1](#tbl1){ref-type="table"}).Figure 1Flow chart of patient enrollment, endpoints, treatments, and relapse. Abbreviations: AIH, autoimmune hepatitis; EMR, electronic medical record.Figure 1Table 1Baseline clinical data and demographic characteristics categorized by treatment endpoint.Table 1Complete remission (*n* = 62)Incomplete remission (*n* = 13)Lost to follow-up (*n* = 11)*P* valueAge, years[§](#tbl1fnsection){ref-type="table-fn"}52 (45--60)48 (41--59)54 (48--65)0.550Sex, female[¶](#tbl1fnpara){ref-type="table-fn"}49 (79.0)13 (100)7 (63.6)0.075BMI, kg/m^2^[§](#tbl1fnsection){ref-type="table-fn"}23.5 (21.1--25.8)23.1 (21.9--24.0)22.3 (19.7--31.4)0.723Underlying disease[¶](#tbl1fnpara){ref-type="table-fn"} Diabetes mellitus6 (9.7)2 (15.4)3 (27.3)0.261 Hypertension4 (6.5)4 (30.8)0 (0)0.012∗ Dyslipidemia15 (24.2)3 (23.1)0 (0)0.188 Thyroid disease3 (4.8)1 (7.7)1 (9.1)0.816 PBC (overlap syndromes)4 (6.5)3 (23.1)2 (18.2)0.137 SLE3 (4.8)0 (0)0 (0)0.548 No underlying disease28 (45.2)1 (7.7)7 (63.6)0.013∗Criteria diagnosis[¶](#tbl1fnpara){ref-type="table-fn"}0.002∗ Definite9 (14.5)0 (0)0 (0) Probable8 (12.9)4 (30.8)7 (63.6) Possible45 (72.6)9 (69.2)4 (36.4)Ultrasonography[¶](#tbl1fnpara){ref-type="table-fn"}0.001∗ Normal26 (41.6)3 (23.1)1 (9.1) Parenchymatous change26 (41.6)7 (53.8)2 (18.2) Cirrhosis9 (14.8)3 (23.1)8 (72.7)Liver histopathology[¶](#tbl1fnpara){ref-type="table-fn"}0.035∗ Typical/compatible29 (46.7)6 (46.2)2 (18.2) Negative13 (21.0)5 (38.4)1 (9.1) Not done20 (32.3)2 (15.4)8 (72.7)Lab[§](#tbl1fnsection){ref-type="table-fn"} Hematocrit (%)35.0 (31.3--38.2)33.6 (31.0--34.0)33.0 (30.0--38.0)0.222 White blood cells (cell/mm^3^)7,000 (5,800--8,700)6,300 (4,800--8,900)9,100 (6,400--12,800)0.293 Platelets (/mm^3^)241,500 (166,500--294,000)118,000 (104,500--296,000)175,000 (75,000--219,000)0.021∗ INR1.29 (1.09--1.47)1.07 (0.96--1.08)1.49 (1.37--2.08)0.008∗ Albumin (g/dL)3.7 (3.2--4.3)3.5 (3.3--4.0)2.8 (2.6--2.9)\<0.001∗ TB (mg/dL)3.3 (0.9--16.6)3.6 (1.2--7.6)12.8 (3.9--16.6)0.195 ALT (U/L)162 (84--482)105 (78--158)90 (71--197)0.049∗ AST (U/L)230 (96--585)120 (71--257)155 (105--225)0.246 ALP (U/L)127 (99--193)183 (104--374)235 (144--316)0.023∗ AST/ALT ratio1.4 (0.7--1.8)1.1 (1.0--1.8)1.8 (1.1--2.1)0.310Child-Pugh score[¶](#tbl1fnpara){ref-type="table-fn"}0.004∗ A29 (50.9)6 (50.0)0 (0) B25 (43.9)5 (41.7)7 (63.6) C3 (5.3)1 (8.3)4 (36.4)Combination treatment[¶](#tbl1fnpara){ref-type="table-fn"}32 (51.6)8 (61.5)4 (36.4)0.465[^1][^2][^3][^4]

The baseline characteristics and laboratory results according to the autoimmune hepatitis treatment regimens are presented in [Table 2](#tbl2){ref-type="table"}. The mean initial dose of prednisolone in the prednisolone monotherapy group was 45 ± 15 (range, 20--60 mg), while the mean initial dose of prednisolone and azathioprine in the combination group was 20 ± 13 (range, 10--60 mg) and 91 ± 29 (range, 50--150 mg), respectively. There were no significant differences in age, sex, BMI, diagnostic criteria, ultra-sonographic findings, liver histopathology, the Child-Pugh scores, and the treatment endpoint between the two groups. The number of patients with primary biliary cholangitis overlap syndromes was significantly higher in the combination group, while patients with no underlying disease(s) was significantly lower. Serum aspartate aminotransferase was significantly higher in the prednisolone monotherapy group.Table 2Baseline clinical data and demographic characteristics categorized by autoimmune hepatitis treatment regimens.Table 2Prednisolone (*n* = 42)Combination (*n* = 44)*P* valueAge, years[§](#tbl2fnsection){ref-type="table-fn"}50 (43--60)54 (46--60)0.409Sex, female[¶](#tbl2fnpara){ref-type="table-fn"}35 (83.3)34 (77.3)0.481BMI, kg/m^2^[§](#tbl2fnsection){ref-type="table-fn"}23.3 (21.5--25.6)23.6 (20.6--26.0)0.983Underlying disease[¶](#tbl2fnpara){ref-type="table-fn"} Diabetes mellitus3 (7.1)8 (18.2)0.125 Hypertension4 (9.5)4 (9.1)0.945 Dyslipidemia8 (19.0)10 (22.7)0.675 Thyroid disease1 (2.4)4 (9.1)0.184 PBC (overlap syndromes)1 (2.4)8 (18.2)0.017∗ SLE2 (4.8)1 (2.3)0.529 No underlying disease23 (54.8)13 (29.5)0.018∗Criteria diagnosis[¶](#tbl2fnpara){ref-type="table-fn"}0.136 Definite6 (14.3)3 (6.8) Probable12 (28.6)7 (15.9) Possible24 (57.1)34 (77.3)Ultrasonography[¶](#tbl2fnpara){ref-type="table-fn"}0.703 Normal15 (35.7)15 (34.1) Parenchymatous change16 (38.1)19 (43.2) Cirrhosis11 (26.2)9 (20.5)Liver histopathology[¶](#tbl2fnpara){ref-type="table-fn"}0.797 Typical/compatible19 (45.2)18 (40.9) Negative8 (19.0)11 (25.0) Not done15 (35.7)15 (34.1)Lab[§](#tbl2fnsection){ref-type="table-fn"} Hematocrit (%)34.0 (30.5--37.1)34.3 (31.9--38.0)0.791 White blood cells (cell/mm^3^)7,910 (5,900--10,200)6,800 (5,400--8,750)0.239 Platelets (/mm^3^)216,000 (161,000--279,500)217,000 (127,000--281,000)0.824 INR1.36 (1.07--1.49)1.24 (1.03--1.48)0.319 Albumin (g/dL)3.6 (2.9--3.9)3.6 (3.0--4.3)0.365 TB (mg/dL)6.2 (1.1--16.0)2.9 (1.0--9.9)0.386 ALT (U/L)188 (82--518)138 (79--269)0.261 AST (U/L)248 (120--705)157 (69--256)0.023∗ ALP (U/L)142 (97--237)130 (106--225)0.832 AST/ALT ratio1.5 (1.0--1.9)1.1 (0.7--1.8)0.060Child-Pugh score[¶](#tbl2fnpara){ref-type="table-fn"}0.485 A14 (36.8)21 (50.0) B20 (52.6)17 (40.5) C4 (10.5)4 (9.5)Treatment endpoint[¶](#tbl2fnpara){ref-type="table-fn"}0.465 Complete remission30 (71.4)32 (72.7) Incomplete remission5 (11.9)8 (18.2) Lost to follow-up7 (16.7)4 (9.1)[^5][^6][^7][^8]

The Cox-proportional hazard model revealed that the prognostic factors related to complete remission included absence of liver cirrhosis, hypertension, and azathioprine exposure, whereas age, sex, BMI, and the initial liver function test were not ([Table 3](#tbl3){ref-type="table"}).Table 3Prognostic factors for complete remission in autoimmune hepatitis.Table 3Univariate Cox hazard analysisMultivariate Cox hazard analysisCrude HR (95%CI)*P* valueAdjusted HR (95%CI)*P* valueAge1.00 (0.99--1.00)0.0521.00 (0.99--1.00)0.206Azathioprine exposure0.67 (0.41--1.12)0.1280.49 (0.28--0.84)0.009∗Female0.72 (0.39--1.33)0.294\--BMI0.98 (0.90--1.06)0.582\--Hypertension0.35 (0.12--0.97)0.043∗0.16 (0.05--0.54)0.003∗Cirrhosis[§](#tbl3fnsection){ref-type="table-fn"}0.48 (0.24--0.98)0.045∗0.37 (0.18--0.76)0.007∗Child Pugh score0.76 (0.50--1.14)0.185\--Platelets1.00 (0.99--1.00)0.076\--Albumin1.04 (0.99--1.09)0.065\--TB1.00 (0.98--1.03)0.755\--ALT1.00 (0.99--1.00)0.072\--AST1.00 (0.99--1.00)0.078\--ALP0.99 (0.99--1.00)0.033∗0.99 (0.99--1.00)0.050AST/ALT ratio1.00 (0.93--1.07)0.953PBC overlap0.39 (0.14--1.07)0.068\--[^9][^10]

Median time to complete remission in the prednisolone monotherapy group was 92 days (95%CI 65--264 days) and 336 days (95%CI 161--562 days) in the combination group ([Figure 2](#fig2){ref-type="fig"}). After adjusting for covariates (age, hypertension, cirrhosis, and alkaline phosphatase), the prednisolone monotherapy group had a significantly shorter median time to complete remission than the combination group (*P* = 0.01).Figure 2Median time to complete remission in patients given the prednisolone monotherapy regimen and those who underwent combination regimen was 92 days (95%CI 65--264) and 336 days (95%CI 161--562), respectively, with a *P* of 0.01. Total median time to remission was 170 days (95%CI 126--336).Figure 2

The prednisolone monotherapy group had higher rates of skin and soft tissue infections (*P* = 0.01) and Cushingoid appearance (*P* = 0.01), but there were no statistically significant differences in the rates of other side effects (cytopenia, myopathy, hyperglycemia, pneumonia, bacteremia, and urinary tract infection; [Table 4](#tbl4){ref-type="table"}).Table 4Comparison of complication rates between two autoimmune hepatitis treatment regimens.Table 4Prednisolone *n* = 42 (%)Combination *n* = 44 (%)*P* valueInfection-Pneumonia3 (7.1)2 (4.5)0.607-Skin and soft tissue10 (23.8)2 (4.5)0.010∗-Primary bacteremia1 (2.4)2 (4.5)0.584-Urinary tract1 (2.4)0 (0)0.303Cytopenia3 (7.1)8 (18.2)0.125Muscle weakness3 (7.1)1 (2.3)0.284Cushing appearance8 (19.0)1 (2.3)0.011∗Hyperglycemia[§](#tbl4fnsection){ref-type="table-fn"}5 (11.9)4 (9.1)0.670[^11]

In addition, the prednisolone monotherapy group had a higher relapse rate than the combination group (odds ratio 6.13, 95% CI 1.72--21.80, *P* = 0.005).

4. Discussion {#sec4}
=============

About 80% of the AIH patients in Srinagarind Hospital were middle-aged woman, as were patients in previous studies \[[@bib2], [@bib3]\]. The complete remission rate in the current study was 72.1%, which is slightly higher than that reported by Czaj et al. \[[@bib22]\]. The group with an incomplete response had nearly double the negative histology for AIH as the responsive group, which may be the reason that treatment was not effective. There have not been any previous studies that have compared median time to remission between these two treatment regimens. Our study found that patients getting the prednisolone monotherapy had a significantly shorter median time to complete remission than patients getting the combination therapy. The total median time to complete remission was 170 days, which was longer than that found in a previous study \[[@bib10]\]; this may be explained a higher initial dose of prednisolone leading to a shorter time to remission. A previous real-world study suggested that an initial prednisolone dose of 40 mg/day with a slower tapering protocol induced an earlier biochemical response than an initial prednisolone dose of 30 mg/day \[[@bib23]\].

As with previous reports, the current study confirmed that liver cirrhosis at the time of AIH diagnosis was a significant poor prognostic factor for treatment outcome \[[@bib11], [@bib13], [@bib14], [@bib15], [@bib16]\]. We also found that absence of hypertension at the time of AIH diagnosis and absence of azathioprine exposure during the treatment period were good prognostic factors for complete remission. Although previous studies reported that younger age, low serum albumin, and high total bilirubin at the time of diagnosis were poor prognostic factors, the current study did not confirm this \[[@bib13], [@bib14], [@bib15]\].

There have not yet been any reports comparing treatment complications between these two treatment regimens. The current study was thus the first to report that the rates of skin and soft tissue infection and Cushingoid appearance in patients treated using the single prednisolone regimen were significantly higher than in those receiving azathioprine with a reduced dosage of prednisolone.

Autoimmune hepatitis has a high relapse rate \[[@bib24]\], and relapse usually occurs within 12 months after remission \[[@bib25], [@bib26]\]. There have, however, been no studies comparing the relapse rates of autoimmune hepatitis treatment regimens. Our study was thus the first to find that the single prednisolone regimen had about a six-times higher relapse rate than azathioprine with a reduced dosage of prednisolone.

The strengths of the current study are that (a) it was larger than previous retrospective studies \[[@bib15], [@bib27]\] and (b) had an average duration of follow-up of 2 years with only a 12% dropout rate. There were, however, some limitations. First, diagnostic liver biopsy could not be performed in some patients (35%) due to their inability to afford the cost of the procedure and unwillingness to accept risk of procedural complications. Second, serum IgG and serum antinuclear antibody titer measurements have only been available in our laboratory for the past few years. Third, our center did not perform liver biopsy to confirm the remission stage due to financial constraints and patient refusal, so we based our remission assessments on symptoms and the normalization of liver function test results. Fourth, data were collected retrospectively and some information was unavailable (i.e., the maintenance dose of prednisolone and long-term complications of prolonged steroid treatment).

In conclusion, the absence of liver cirrhosis and hypertension at the time of diagnosis and no azathioprine exposure during the treatment period were good prognostic factors for complete remission. Patients receiving prednisolone monotherapy had a significantly shorter median time to complete remission than patients receiving a combination therapy. Notwithstanding, patients receiving the combination therapy had lower rates of treatment complications and relapse than those receiving the prednisolone monotherapy.Key points-Absence of liver cirrhosis and hypertension at diagnosis and no azathioprine exposure during treatment were favorable prognostic factors for complete remission of type 1 autoimmune hepatitis.-The prednisolone monotherapy group had a significantly shorter median time to complete remission, but higher rates of treatment complications and a higher relapse rate than the combination group.
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[^1]: *P* values calculated using Kruskal-Wallis test or Pearson\'s chi-squared test.

[^2]: Abbreviations: PBC, primary biliary cholangitis; SLE, systemic lupus erythematosus; INR, international normalized ratio; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.

[^3]: Data presented as median (1^st^ -- 3^rd^ quartile range).

[^4]: Data presented as number (percentage).

[^5]: *P* values calculated using Wilcoxon rank-sum test or Pearson\'s chi-squared test.

[^6]: Abbreviations: PBC, primary biliary cholangitis; SLE, systemic lupus erythematosus; INR, international normalized ratio; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.

[^7]: Data presented as median (1^st^ -- 3^rd^ quartile range).

[^8]: Data presented as number (percentage).

[^9]: Abbreviations: BMI, body mass index; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; PBC, primary biliary cholangitis.

[^10]: Cirrhosis was diagnosed by ultrasonography.

[^11]: Hyperglycemia that leads patients to be admitted or treated with antihyperglycemic drugs.
